Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Guidance for Therapy in Thyroid Cancer and Head/Neck Malignancies
NCT04589624Phase 1Recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Aug 2020
- Primary completion
- May 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [1-13C]pyruvate in thyroid cancer and head and neck cancer (HNC) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Metabolic imaging data from hyperpolarized magnetic resonance imaging (hpMRI) methods at 1 year. Started Aug 2020; status: recruiting.
02
Drugs
[1-13C]pyruvate
03
Conditions
thyroid cancerhead and neck cancer (HNC)
Beyond the preview
Go deeper on NCT04589624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04589624.